depending on the manufacturing process used.
test 1
Solution A:
a 0.1% (w/v) solution of monobasic potassium phosphate adjusted with 1 N sodium hydroxide to a pH of 6.0.
Solution B:
methanol.
Mobile phase
Use variable mixtures of
Solution A and
Solution B as directed for
Chromatographic system. Make adjustments if necessary (see
System Suitability under
Chromatography
621
).
Standard solution
Transfer about 12 mg of
USP Meloxicam RS, accurately weighed, to a 20-mL volumetric flask, dissolve in 5 mL of methanol and 0.3 mL of 1 N sodium hydroxide, dilute with methanol to volume, and mix. Transfer 2 mL of this solution to a 100-mL volumetric flask, dilute with methanol to volume, and mix.
Test solution
Transfer about 80 mg of Meloxicam, accurately weighed, to a 20-mL volumetric flask, dissolve in 5 mL of methanol and 0.3 mL of 1 N sodium hydroxide, dilute with methanol to volume, and mix.
Chromatographic system (see Chromatography
621
)
The liquid chromatograph is equipped with a variable wavelength or multi-wavelength UV detector and a 4.6-mm × 15-cm column that contains 5-µm packing L1. The column temperature is maintained at 45

. The flow rate is about 1 mL per minute, and the detection wavelengths are 260 nm and 350 nm. The chromatograph is programmed as follows.
Time (minutes) |
Solution A
(%) |
Solution B
(%) |
Elution |
02 |
60 |
40 |
isocratic |
210 |
60®30 |
40®70 |
linear gradient |
1015 |
30 |
70 |
isocratic |
1515.1 |
30®60 |
70®40 |
linear gradient |
15.118 |
60 |
40 |
equilibration |
Chromatograph the
System suitability solution, and record the peak responses as directed for
Procedure: the relative retention times based on the meloxicam peak at about 7 minutes are listed in
Table 1. At 350 nm, the resolution,
R, between meloxicam related compound A and meloxicam is not less than 3.0; at 260 nm, the resolution,
R, between meloxicam related compound B and meloxicam is not less than 3.0. Chromatograph the
Standard solution, and record the peak responses as directed for
Procedure: the relative standard deviation for replicate injections is not more than 10%.
Procedure
Separately inject equal volumes (about 5 µL) of the
Standard solution and the
Test solution into the chromatograph, record the chromatograms at detection wavelengths of 260 nm and 350 nm, and measure the peak responses. Calculate the percentage of each impurity in the portion of Meloxicam taken by the formula:
100(CS / CT)(1 / F)(rU / rS)
in which
CS is the concentration, in mg per mL, of
USP Meloxicam RS in the
Standard solution; CT is the concentration, in mg per mL, of Meloxicam in the
Test solution; F is the relative response factor (see
Table 1);
rU is the peak response of each impurity obtained from the
Test solution; and
rS is the peak response of meloxicam at 350 nm obtained from the
Standard solution.
[noteFor the specified impurities, calculate the percentage content of each impurity, using the
Test solution peak responses recorded at the detection wavelength given in
Table 1. For an unknown impurity, calculate the percentage content, using peak responses recorded at the wavelength that gives the greater response.
]
Table 1
Compound |
Approximate Relative Retention Time |
Wavelength (nm) |
Relative Response Factor (F) |
Limit (w/w, %) |
4-Hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid ethylester 1,1-dioxide (meloxicam related compound A) |
1.4 |
350 |
0.5 |
0.1 |
2-Amino-5-methyl-thiazole (meloxicam related compound B) |
0.4 |
260 |
1.0 |
0.1 |
4-Hydroxy-2-methyl-N-(N¢-methyl-5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide |
1.9 |
350 |
1.0 |
0.05 |
4-Hydroxy-2-methyl-N-(N¢-ethyl-5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide |
1.7 |
350 |
1.0 |
0.05 |
Individual unknown impurity |
|
260/350 |
1.0 |
0.1 |
Total impurity |
|
|
|
0.3 |
test 2
If an article complies with this test, the labeling indicates that it meets the requirements of
Related compounds Test 2.
Solution A and Solution B
Prepare as directed in Test 1.
Mobile phase
Use variable mixtures of
Solution A and
Solution B as directed for
Chromatographic system. Make adjustments if necessary (see
System Suitability under
Chromatography
621
).
Diluent A:
a mixture of Diluent B and 0.4 N sodium hydroxide (50:3).
Diluent B:
a mixture of water and methanol (60:40).
Standard stock solution 1
Prepare a solution having a known concentration of about 50 µg per mL of
USP Meloxicam RS in
Diluent A. Transfer 2 mL of the solution to a 10-mL volumetric flask, dilute with
Diluent B to volume, and mix.
Standard solution
Transfer 1 mL each of Standard stock solution 1 and Standard stock solution 2 into a 10-mL volumetric flask, dilute with Diluent B to volume, and mix.
System suitability stock solution
Prepare a solution containing about 2 mg per mL of
USP Meloxicam RS in
Diluent A.
System suitability solution
Transfer 5 mL of System suitability stock solution and 1 mL of Standard stock solution 2 into a 10-mL volumetric flask, dilute with Diluent B to volume, and mix.
Test solution
Transfer about 20 mg of Meloxicam, accurately weighed, to a 20-mL volumetric flask, dissolve in 10 mL of Diluent A, dilute with Diluent B to volume, and mix.
Chromatographic system (see Chromatography
621
)
The liquid chromatograph is equipped with a variable wavelength or multi-wavelength UV detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1. The column temperature is maintained at 45

. The flow rate is about 1 mL per minute and the detection wavelengths are 260 nm and 350 nm. The chromatograph is programmed as follows.
Time (minutes) |
Solution A
(%) |
Solution B
(%) |
Elution |
025 |
45 |
55 |
isocratic |
2530 |
45®30 |
55®70 |
linear gradient |
3040 |
30 |
70 |
isocratic |
4045 |
30®45 |
70®55 |
linear gradient |
4550 |
45 |
55 |
equilibration |
Chromatograph the
System suitability solution, and record the peak responses as directed for
Procedure: the relative retention times based on the meloxicam peak at about 5 minutes are listed in
Table 2; and the resolution,
R, between meloxicam related compound D and meloxicam at 350 nm is not less than 5.0. Chromatograph the
Standard solution, and record the peak responses as directed for
Procedure: the relative standard deviation for replicate injections is not more than 5.0% for meloxicam related compound C and for meloxicam related compound D at 350 nm; and not more than 5.0% for meloxicam related compound B at 260 nm.
Procedure
Separately inject equal volumes (about 20 µL) of the
Standard solution and
Test solution into the chromatograph, record the chromatograms at detection wavelengths of 260 nm and 350 nm, and measure the peak responses. Calculate the percentage of each impurity in the portion of Meloxicam taken by the formula:
100(CS / CT)(rU / rS)
in which
CS is the concentration, in mg per mL, of the corresponding USP Related Compound RS in the
Standard solution [noteUse the concentration of the
USP Meloxicam RS for unknown impurities.
];
CT is the concentration, in mg per mL, of Meloxicam in the
Test solution; rU is the peak response of each impurity obtained from the
Test solution; and
rS is the peak response of the corresponding related compound obtained from the
Standard solution. [noteUse the peak response of the
USP Meloxicam RS for unknown impurities; for the specified impurities, calculate the percentage content of each impurity using the
Test solution peak responses recorded at the detection wavelength given in
Table 2. For an unknown impurity, calculate the percentage content using peak responses recorded at the wavelength that gives the greater response.
]
Table 2
Compound |
Approximate Relative Retention Time |
Wavelength (nm) |
Limit (w/w, %) |
2-Amino-5-methyl-thiazole (meloxicam related compound B) |
0.8 |
260 |
0.1 |
Isopropyl-4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate-1,1-dioxide (meloxicam related compound C) |
3.2 |
350 |
0.1 |
4-Methoxy-2-methyl-N-(5-methyl-1,3-thiazol-2yl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide (meloxicam related compound D) |
2.4 |
350 |
0.1 |
Individual unknown impurity |
|
260/350 |
0.1 |
Total impurity |
|
|
0.3 |